CVS to Restore Coverage for Zepbound and Add Eli Lilly’s Foundayo Pill

1-Minute Brief

CVS's decision may expand access to weight-loss medications for patients who previously faced coverage restrictions.

Key Facts

• CVS will add Zepbound coverage starting October 1.
• CVS's move is described as a significant change for patients seeking weight-loss treatments.
• CVS will begin covering Eli Lilly's newly approved Foundayo pill on June 1.
• CVS Caremark had previously removed Zepbound from its drug plans before this announcement.
• The coverage changes follow recent developments regarding the pricing and approval of these medications.

What Happened

CVS announced it will restore coverage for Eli Lilly’s weight-loss drug Zepbound on October 1 and add coverage for the newly approved Foundayo pill on June 1.

Why It Matters

The decision could increase patient access to popular weight-loss drugs, which have been in high demand and previously faced insurance coverage limitations.

What's Next

Patients using CVS Caremark plans may be able to access Zepbound and Foundayo under their coverage on the specified dates. Observers will watch for impacts on patient uptake and insurance trends.